ReviewExpert review of neurotherapeutics2008
Antiangiogenic therapy in brain tumors.
Review in Expert review of neurotherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Development and validation: a whole-tumor histogram model based on intravoxel incoherent motion diffusion-weighted imaging for diagnosing tumor deposits in rectal cancer.Abdominal radiology (New York) · 2026Article
- Review
- Identification of Key Biomarkers Associated with Glioma Hemorrhage: Evidence from Bioinformatic Analysis and Clinical Validation.Journal of molecular neuroscience : MN · 2025Article
- Solid Lipid Nanoparticles Encapsulating a Benzoxanthene Derivative in a Model of the Human Blood-Brain Barrier: Modulation of Angiogenic Parameters and Inflammation in Vascular Endothelial Growth Factor-Stimulated Angiogenesis.Molecules (Basel, Switzerland) · 2024Article
- Understanding the Role of Endothelial Cells in Glioblastoma: Mechanisms and Novel Treatments.International journal of molecular sciences · 2024Review
- The "Superoncogene" Myc at the Crossroad between Metabolism and Gene Expression in Glioblastoma Multiforme.International journal of molecular sciences · 2023Review
- Masson Tumor of the Central Nervous System: A Case Report and Review of Literature.The American journal of case reports · 2022Review
- Angiogenesis and Its Targeting in Glioblastoma with Focus on Clinical Approaches.Cell journal · 2022Article
- The cerebral microvasculature: Basic and clinical perspectives on stroke and glioma.Microcirculation (New York, N.Y. : 1994) · 2021Review
- Optimal control methods for drug delivery in cancerous tumour by anti-angiogenic therapy and chemotherapy.IET systems biology · 2021Article
- Roles of Non-coding RNAs and Angiogenesis in Glioblastoma.Frontiers in cell and developmental biology · 2021Review
- The Normal and Brain Tumor Vasculature: Morphological and Functional Characteristics and Therapeutic Targeting.Frontiers in physiology · 2021Review
- Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer.Cell · 2020Article
- Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.Molecular neurobiology · 2020Review
- Theranostic Nanomedicine for Malignant Gliomas.Frontiers in bioengineering and biotechnology · 2019Review
- Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer.Nanotheranostics · 2018Review
- Insights into molecular therapy of glioma: current challenges and next generation blueprint.Acta pharmacologica Sinica · 2017Review
- Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro.Journal of experimental & clinical cancer research : CR · 2016Article
- Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Oncotarget · 2015Article
- Adaptation to antiangiogenic therapy in neurological tumors.Cellular and molecular life sciences : CMLS · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Angiogenesis, the recruitment of new blood vessels, is an essential component of tumor progression. Malignant brain tumors are highly vascularized and their growth is angiogenesis-dependent. As such, inhibition of the sprouting of new capillaries from pre-existing blood vessels is one of the most promising antiglioma therapeutic approaches. Numerous classes of molecules have been implicated in regulating angiogenesis and, thus, novel agents that target and counteract angiogenesis are now being developed. The therapeutic trials of a number of angiogenesis inhibitors as antiglioma drugs are currently under intense investigation. Preliminary studies of angiogenic blockade in glioblastoma have been promising and several clinical trials are now underway to develop optimum treatment strategies for antiangiogenic agents. This review will cover state-of-the-art antiangiogenic targets for brain tumor treatment and discuss future challenges. An increased understanding of the angiogenic process, the diversity of its inducers and mediators, appropriate drug schedules and the use of these agents with other modalities may lead to radically new treatment regimens to achieve maximal efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.